FLORE
Repository istituzionale dell'Università degli Studi di Firenze

A new prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis

(Article begins on next page)

14 May 2024

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

Francisco Cervantes, Brigitte Dupriez, Arturo Pereira, Francesco Passamonti, John T. Reilly, Enrica Morra, Alessandro M. Vannucchi, Ruben A. Mesa, Jean-Loup Demory, Giovanni Barosi, Elisa Rumi and Ayalew Tefferi

Updated information and services can be found at:
http://bloodjournal.hematologylibrary.org/cgi/content/full/113/13/2895

Articles on similar topics may be found in the following *Blood* collections:
Free Research Articles (613 articles)
Myeloid Neoplasia (46 articles)
Clinical Trials and Observations (2536 articles)

Information about reproducing this article in parts or in its entirety may be found online at:
http://bloodjournal.hematologylibrary.org/misc/rights.dtl#repub_requests

Information about ordering reprints may be found online at:
http://bloodjournal.hematologylibrary.org/misc/rights.dtl#reprints

Information about subscriptions and ASH membership may be found online at:
http://bloodjournal.hematologylibrary.org/subscriptions/index.dtl

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

Francisco Cervantes,[1] Brigitte Dupriez,[2] Arturo Pereira,[1] Francesco Passamonti,[3] John T. Reilly,[4] Enrica Morra,[5] Alessandro M. Vannucchi,[6] Ruben A. Mesa,[7] Jean-Loup Demory,[2] Giovanni Barosi,[8] Elisa Rumi,[3] and Ayalew Tefferi[7]

[1]Hematology Department, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain; [2]Centre Hospitalier, Lens and Lille, France; [3]Hematology Division, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S Matteo, University of Pavia, Pavia, Italy; [4]Royal Hallamshire Hospital, Sheffield, United Kingdom; [5]Universita Milano-Niguarda, Milan, Italy; [6]University of Florence, Florence, Italy; [7]Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN; and [8]Unit of Clinical Epidemiology, Center for the Study of Myelofibrosis, Fondazione IRCCS Policlinico S Matteo, Pavia, Italy

Therapeutic decision-making in primary myelofibrosis (PMF) is becoming more challenging because of the increasing use of allogeneic stem cell transplantation and new investigational drugs. To enhance this process by developing a highly discriminative prognostic system, 1054 patients consecutively diagnosed with PMF at 7 centers were studied. Overall median survival was 69 months (95% confidence interval [CI]: 61-76). Multivariate analysis of parameters obtained at disease diagnosis identified age greater than 65 years, presence of constitutional symptoms, hemoglobin level less than 10 g/dL, leukocyte count greater than 25×10^9/L, and circulating blast cells 1% or greater as predictors of shortened survival. Based on the presence of 0 (low risk), 1 (intermediate risk-1), 2 (intermediate risk-2) or greater than or equal to 3 (high risk) of these variables, 4 risk groups with no overlapping in their survival curves were delineated; respective median survivals were 135, 95, 48, and 27 months (P < .001). Compared with prior prognostic models, the new risk stratification system displayed higher predictive accuracy, replicability, and discriminating power. In 409 patients with assessable metaphases, cytogenetic abnormalities were associated with shorter survival, but their independent contribution to prognosis was restricted to patients in the intermediate-risk groups. *JAK2*V617F did not cluster with a specific risk group or affect survival. (Blood. 2009;113: 2895-2901)

Introduction

Primary myelofibrosis (PMF)[1] is classified as a chronic myeloproliferative disorder and characterized by variable degrees of cytopenia(s) and/or cytosis, a leukoerythroblastic blood picture, bone marrow fibrosis, and extramedullary hematopoiesis often resulting in hepatosplenomegaly.[2] From a pathogenesis standpoint, the disease features clonal proliferation involving pluripotent hematopoietic stem cells,[3,4] and clonal cell–derived cytokines are implicated for some of the disease aspects such as bone marrow fibrosis and extramedullary hematopoiesis.[2] Most recently, *JAK2*[5-7] and *MPL*[8-10] mutations were described in approximately 50% and 10% of patients with PMF, respectively. However, the precise pathogenetic contribution of these mutations is currently not well defined.

PMF usually affects subjects with advanced age,[11] but young people are not necessarily spared.[12] Reported median survivals are variable and in the range of 4-7 years.[13,14] Previous studies have identified several adverse prognostic factors for survival, including advanced age,[15-19] marked anemia,[13-22] leukocytosis or leukopenia,[14,16,18,22] abnormal karyotype,[18,23-25] constitutional symptoms,[13,14,17,22] and presence of circulating blasts.[13,14,22] Based on some of these variables, several prognostic scoring systems have been proposed.[12,13,18,19,22,26] More recently, the prognostic value of blood CD34$^+$ cell count[27,28] and *JAK*2 mutational status[29-31] has also been evaluated.

Current drug therapy for PMF has not been shown to influence survival and is often used for palliative purposes only.[32] To get out of this therapeutic deadlock, there is growing use of allogeneic stem cell transplantation (allo-SCT)[33-38] and, more recently, anti-JAK2–targeted therapy.[32] Patient selection for these and other therapeutic approaches in PMF is often challenging and is the main reason to undertake the current large multicenter study, to accurately identify prognostic factors that would facilitate therapeutic decision making for the individual patient.

Methods

Patients and diagnostic criteria

After approval from the Institutional Review Board of each participating study center, the databases of the 7 participant institutions were screened, and a total of 1131 consecutive patients diagnosed with PMF during the period of January 1980 to April 2007 were analyzed. By definition, cases of post–polycythemia vera (post-PV) or post–essential thrombocythemia (post-ET) myelofibrosis[1] were not considered. After a systematic individual case review, 19 patients were excluded due to the following reasons: 3 patients met criteria for blastic transformation at presentation (blast cells in bone marrow or blood ≥ 20%), 1 had extreme leukocytosis (> 150×10^9/L), 9 met criteria for chronic myelomonocytic leukemia, and 6 had hemoglobin levels that would qualify for a diagnosis of PV. In addition, 58 more patients were excluded by applying the diagnostic criteria for PMF recently established by the World Health Organization (WHO) classification system,[39] because diagnosis in these excluded cases had been based on the

presence of isolate thrombocytosis ($> 450 \times 10^9$/L) with grade 1 bone marrow fibrosis that was not associated with palpable splenomegaly, anemia, leukoerythroblastosis, or increased serum lactate dehydrogenase (LDH) levels. In the end, therefore, 1054 patients were submitted for analysis of prognostic factors.

Due to the long study period, diagnosis of PMF was made according to the criteria accepted at the time when the patient was diagnosed. In all cases, presence of an increased reticulin and/or collagen bone marrow content without any apparent cause (such as chronic myeloid leukemia, PV, myelodysplasia, lymphoproliferative disorders, scleroderma, primary pulmonary hypertension, or others) was required, in addition to the presence of features typical of the disease, including palpable splenomegaly, leukoerythroblastosis, or histologic demonstration of myeloid metaplasia. Cases of the so-called "prefibrotic" form of PMF,[39,40] characterized by lack of marrow fibrosis with highly dysplastic megakaryocytes, usually accompanied by thrombocytosis, but without anemia, splenomegaly, or leukoerythroblastosis, were not considered, because most patients were diagnosed before this histologic variant of PMF was recognized by the WHO classification and to minimize the inadvertent inclusion of patients with ET.[41,42]

Treatment

Disease management was variable and usually based on the disease characteristics in every individual patient. It included a wait-and-see approach until disease progression in asymptomatic patients, single-agent oral chemotherapy (mainly hydroxyurea, but also busulfan, 6-mercaptopurine, pipobroman, and thioguanine), androgens, erythropoiesis stimulating agents, prednisone, interferon-α, anagrelide, immunomodulatory agents such as thalidomide and lenalidomide and, in few instances, intravenous cytotoxic agents such as radiophosphorus and cladribine. A total of 111 patients underwent splenectomy during the study period, 5 received allo-SCT with a standard (n = 4) or a reduced-intensity conditioning (RIC) regimen (n = 1), and 2 autologous SCT.

Data evaluated

The initial variables selected for prognostic assessment were those previously shown to be of prognostic value in PMF, those clinically meaningful, and possible confounders (namely, diagnostic period and series of origin), provided that they were available in the majority of patients. With the above premises, the following characteristics were analyzed for prognostic significance: diagnostic period (before and after 1995), institution of origin, patient's sex, age greater than 65 years, presence of constitutional symptoms (weight loss $> 10\%$ of the baseline value in the year preceding PMF diagnosis and/or unexplained fever or excessive sweats persisting for more than 1 month), hemoglobin (Hb) less than 10 g/dL, leukocyte count (considered at the cutoff levels of 4×10^9/L, 20×10^9/L, 25×10^9/L, and 30×10^9/L), presence ($\geq 1\%$) of circulating blasts in peripheral blood, and platelet count less than 100×10^9/L. These variables were available in 96.6% to 100% of patients. At a further step, other variables available in a lower proportion of patients were also analyzed, including monocyte counts greater than 1×10^9/L (counts available in 65.4% of cases), presence or not of abnormalities in a karyotype obtained from marrow or unstimulated blood (assessable in 409 patients), *JAK*2 mutational status (345 patients), and blood CD34$^+$ cell count (150 cases).

Statistical methods

The major outcome was survival from diagnosis, and it was estimated using the Kaplan-Meier method.[43] The effect of the potential prognostic factors on survival was evaluated by the Cox proportional hazards (PH) regression.[44] In every Cox model, the PH assumption was checked by graphical methods and by the Grambsch-Therneau test.[45]

The final prognostic model was identified through a stepwise selection process based on a z test of the regression coefficients. Initially, all potential risk factors and confounders were included in the multivariate Cox model. At each step, variables with a *P* value for the z test greater than the cutoff were excluded from the model, and the remaining ones were tested again for their independent association with survival until no more variables met the criteria for exclusion. To safeguard against associations occurring by chance due to multiple simultaneous tests, the cutoff values for the z test were Bonferroni-adjusted by dividing 0.05 by the number of covariates in the model at each step.

The prognostic scoring system was evaluated by calculating its discriminating power, compared with that of currently used PMF prognostic systems, and its positive predictive accuracy for actual survival longer (or shorter) than definite time periods from diagnosis. The discriminating power was measured by the Harrell's C concordance index,[46] which represents the proportion of all possible pairs of patients in which the ordering of the risk of death, as predicted by the model, agrees with the observed outcome, after excluding tied observations. Values can range from 0 to 1, with values close to 1 indicating that the scoring system almost perfectly discriminates between patients with different risk of death, while those close to 0.5 indicate that the model's discriminating power is not better than chance alone. Bias-corrected 95% confidence intervals (CIs) for the estimated Harrell index were calculated using resampling with 500 replicates.

The positive predictive accuracy of a prognostic subgroup for actual survival is the proportion of patients in this subgroup who survive longer (or shorter) than a given time cutoff. It was calculated after excluding patients censored before the cutoff, whose actual survival cannot yet be known for certain, as previously described.[47]

The replicability of the prognostic scoring system was tested by bootstrap resampling. One thousand samples, the same size as the original series, were built through random extraction with reposition, so that in each sample, a given patient might either not be represented at all or represented once, twice, or more times. The parameters assessed by resampling were the 95% CI for the hazard ratio of the prognostic factors identified at the Cox regression model and the 95% CI for the 75th, 50th, and 25th percentiles of survival time for each prognostic subgroup. Resampling allows verifying that the prognostic factors identified at the Cox model and the derived prognostic subgroups were not critically dependent on the particular composition of the study series.

The relative survival is the ratio of the mortality observed in the series to the yearly age- and sex-adjusted mortality of the general population for the country of origin and background life span after diagnosis. It permits to evaluate the intrinsic prognostic value of variables like age and sex after excluding their demographic-driven effect on mortality and to compare the survival of patients diagnosed over distant time periods or in countries with a different background life expectancy. Relative survival analysis allows to identify disease-specific prognostic factors even whether the ultimate cause of death can be attributed or not to the disease under study. Relative survival curves were computed using the method described by Hakulinen,[48] and the relative survival values used in the multivariate analysis were calculated by the Ederer II method.[49] The independent association of the potential prognostic factors with relative survival was evaluated by multivariate Poisson regression according to the methods described by Dickman et al.[50] Country-specific yearly age- and sex-adjusted mortality rates from the year of diagnosis were obtained from the Human Mortality Database (http://www.mortality.org).

Comparisons between variables were done using the Chi-square test for variables expressed as proportions and the Mann-Whitney test for ordered or continuous variables. The log-rank test was used to compare Kaplan-Meier survival curves. All tests were 2-sided, and *P* values less than .05 were considered significant. All analyses were conducted using the STATA software (http://www.stata.com). For relative survival analysis, the STATA routines developed by Dickman (Karolinska Institutet, Stockholm, Sweden; available at http://www.pauldickman.com) were used.

Results

Patients' features at presentation

Table 1 summarizes the main clinical and laboratory features of the 1 054 patients at diagnosis. As can be seen, the median age was 64 years; 178 patients (16.9%) were younger than 50 years, and

Table 1. Main clinicohematologic characteristics at diagnosis of primary myelofibrosis in 1054 patients

Feature	Median (range)	Patients	Percent (%) of patients
Age, y	64 (10-90)		
Sex, M/F		638/416	60.5/39.5
Constitutional symptoms		281	27
Palpable splenomegaly		681*	89
Palpable hepatomegaly		365†	50
Hb, g/dL	10.9 (1.7-16.4)		
WBC count, $\times 10^9$/L	9.2 (0.7-108)		
Platelets, $\times 10^9$/L	277 (2-3 279)		
$> 400 \times 10^9$/L		321	30.5
$\leq 100 \times 10^9$/L		174	16.5
Blood blasts ≥ 1%		370‡	36.4

Number of patients with available information: *n = 768; †n = 735; ‡n = 1018.

54 patients (5.1%) were younger than 40 years. Fifty percent of patients had been diagnosed before 1995. Of the 689 patients with available monocyte count, 15% had values greater than 10^9/L. Bone marrow or unstimulated blood karyotype (n = 409) showed abnormalities in 30% of cases. Of the 345 patients assessed for *JAK*2 status, 59% showed the mutation. Median value for the initial CD34$^+$ cell blood count (n = 150) was 35 (range: 0-1575) $\times 10^6$/L.

Survival and causes of death

At the time of analysis, 517 patients (49%) had died. Figure 1 shows the actuarial survival curve of the series. Median survival was 69 months (95% CI: 61-76). Among patients in whom the final cause of death was known, transformation to acute leukemia was the most frequent cause (86 patients), followed by PMF progression without acute transformation (50 cases), thrombosis and cardiovascular complications (37 cases), infection (n = 29) or bleeding (n = 14) out of the setting of acute transformation, portal hypertension (n = 12), and other causes (n = 48, including 12 cases of second neoplasias). Two patients died from complications of transplantation.

Prognostic factors

In the first step of the stepwise Cox model, 3 variables were excluded: series of origin, diagnostic period, and white blood cell (WBC) count less than 4×10^9/L. The variable sex was removed in the second step. No additional variables were excluded in the third step, but neither the whole model nor the variable thrombocytope-

Table 2. Risk factors at presentation of primary myelofibrosis selected at the stepwise Cox regression model for significant association with shorter survival*

Risk factor	Frequency in the series, %	Hazard ratio (95% CI)	z test	*P*
Age > 65 y	44.6	1.95 (1.61-2.36)	6.84	$< .001$
Constitutional symptoms	26.4	1.97 (1.62-2.40)	6.77	$< .001$
Hb < 10 g/dL	35.2	2.89 (2.46-3.61)	11.24	$< .001$
WBC count $> 25 \times 10^9$/L	9.6	2.40 (1.83-3.14)	6.37	$< .001$
Blood blasts > 1%	36.2	1.80 (1.50-2.17)	6.29	$< .001$

*In 1001 patients with the 5 variables available.

nia (platelets $< 100 \times 10^9$/L) met the PH assumption. Further investigation on thrombocytopenia was then performed, disclosing that it was strongly associated with the variable Hb less than 10 g/dL (χ^2 test = 80.8, $P < .001$) and that it did not have prognostic significance in patients without Hb less than 10 g/dL (log-rank $\chi^2 = 0.01$, $P = .9$), while this latter variable retained its prognostic weight in patients without thrombocytopenia (log-rank $\chi^2 = 53.3$, $P < .001$). Because of this collinearity effect, the variable thrombocytopenia was removed from the Cox regression. The resulting prognostic model and every remaining covariate then met the PH assumption, whereas the regression's log-likelihood decreased by only 3% with regard to the model including thrombocytopenia, showing that this variable contributed little to the model's goodness of fit. Table 2 shows the 5 variables finally associated with shorter survival and their frequency in the 1001 patients of the series with the complete set of data.

Prognostic score

Because there were no marked differences in the hazard ratios of the 5 prognostic variables, for the sake of simplicity, 1 point was assigned to each one of them. As a result, the patients' score could range from a minimum of 0 to a maximum of 5. Only 4 patients in the series had a score of 5. In addition, overlapping was observed in the 95% CI of the median survival of patients with scores 3 and 4, whereas no such overlapping was seen in patients with scores 0, 1, and 2. Therefore, patients with scores 3, 4, and 5 were pooled into a single group, and 4 prognostic groups were finally considered: low risk (no poor prognostic factor, including 22% of the patients; median survival 135 months); intermediate risk-1 (1 poor prognostic factor, 29% of the patients; median survival 95 months); intermediate risk-2 (2 prognostic factors; 28% of the patients; median survival 48 months); and high risk (3 or more prognostic factors, 21% of the patients; median survival 27 months; $P < .001$; Table 3 and Figure 2).

By Harrell's C index, the new score proved to have higher discriminating power than Dupriez, Cervantes, and Mayo prognostic scores (Table S1). Figures S1A through C (available on the *Blood* website; see the Supplemental Materials link at the top of the online article) show the survival curves of the risk groups of the series according to the above mentioned scores.

Figure 1. Actuarial survival curve of the overall series.

Table 3. Definition, frequency, and survival of the risk groups of the prognostic scoring system of primary myelofibrosis

| Risk group	No. of factors	Proportion of patients, %	Median survival (mo; 95% CI)	Proportion of deaths, %
Low	0	22	135 (117-181)	32
Intermediate-1	1	29	95 (79-114)	50
Intermediate-2	2	28	48 (43-59)	71
High	> 3	21	27 (23-31)	73

Figure 2. Actuarial survival curves of the 4 risk groups of patients according to the new PMF prognostic system.

Figure 4. Relative survival of the 4 risk groups compared with that of the general population. Expected survival (□), observed survival (●), and relative survival (○) with 95% CI.

Several variations of the model were tested. Thus, when 70 years was used as the cutoff for age, a decrease in the discriminating power of the model was observed. This was even more pronounced when the variables age and constitutional symptoms were removed from the model. When the prognostic value of the monocytosis was tested in the subgroup of 675 patients with the data, it did not increase the prognostic weight of the model. Patients without splenomegaly at diagnosis survived longer than the remainder, but the difference did not reach statistical significance, whereas the variable splenomegaly did not improve the PMF prognostic score. On the other hand, the possible effect of splenectomy in the patients' evolution was not evaluated, as the study was designed to analyze the prognostic significance of presenting and not evolutive data.

The results of the validation of the PMF prognostic score are shown in Figures S2 and S3.

Analysis of the relative mortality

Figure 3 depicts the relative survival of the series compared with that of the general population. As can be seen, once the demographic effects of age, sex, country of origin, and year of diagnosis were excluded, a marked effect of the disease on the patients' survival was observed. Indeed, mortality at 5 and 10 years from diagnosis was 40% and 60% greater, respectively, than the expected mortality in a general population with similar demographic characteristics. Beside, the 5 prognostic factors identified at the stepwise Cox regression model also proved to be the ones significantly influencing on relative survival (data not shown).


Figure 3. Relative survival of the series compared with that of the general population.

Figure 4 shows the relative survival of the 4 risk groups. As can be observed, during the first 5 years, the relative survival of patients in the low-risk group did not differ significantly from that of the general population, being shorter only after such period of time. In patients in the intermediate risk-1 group, the influence on survival was noted only after 3 years, whereas in the intermediate risk-2 group, such an effect was evident since the time of diagnosis, with this effect being even more pronounced in the high-risk group.

Other variables analyzed

In patients with available karyotype (n = 409), presence of cytogenetic abnormalities was associated with Hb less than 10 g/dL ($P < .001$) and showed a significant association with shorter survival even after adjustment for the prognostic score ($P = .01$). Of note, the presence of an abnormal karyotype contributed to the prognosis, but only in the 2 intermediate-risk groups and not in the high- and low-risk groups.

In patients assessed for JAK2 status, a significant association was found between presence of the mutation and age greater than 65 years ($P = .002$). However, no association was observed between JAK2 status and the prognostic score or the survival.

In patients with available blood CD34$^+$ cell count at diagnosis, this parameter correlated with blood blasts greater than or equal to 1% ($P = .004$), but not with prognostic score or survival. Although CD34$^+$ cell counts greater than 300×10^9/L (n = 11) were associated with shorter survival, their prognostic value disappeared when adjusted by prognostic score.

Discussion

PMF is a heterogeneous disease in its presentation[32] and evolution. Median survival is highly variable; a proportion of patients die shortly after diagnosis, whereas a few survive for 2 decades or longer.[13,14] This fact has stimulated identification of prognostic factors and, as a result, several prognostic systems have been proposed. As PMF treatment is essentially palliative, allo-SCT is increasingly being used,[33-38] and newer drugs are being tested in these patients.[32] Although the mortality of RIC allo-SCT is lower than that of conventional allo-SCT,[35-38] there are still some

associated mortality and morbidity. Therefore, prognostic stratification of PMF patients is important to make treatment decisions. However, given the low frequency of the disease, to date, prognostic studies have been performed in series including a relatively small number of patients. In this sense, the present study, in which more than 1 000 patients from 7 institutions were analyzed, represents the largest prognostic study ever performed in this disease.

Median survival of patients in the present series was 5.7 years. Patients diagnosed after 1995 survived slightly longer than those diagnosed before ($P = .045$), but the prognostic significance of date of diagnosis disappeared at multivariate analysis. As expected from previous observations, an initial hemoglobin level of less than 10 g/dL was the variable with the highest impact on survival.[13-22] Presence of constitutional symptoms is also another previously well-established risk factor in PMF.[13,14,17,22] It is to be noted that this parameter includes objective measures such as weight loss and fever and that the temptation to exclude it based on its subjective elements would significantly reduce the discriminating power of the current prognostic model. In the current study, leukocyte count greater than 25×10^9/L performed better, as an adverse risk factor, compared with the previously described cutoff level of 30×10^9/L.[14,22] In addition, the new leukocyte threshold resulted in a higher number of informative patients in terms of patient stratification. In contrast, we could not confirm the poor prognostic influence of either low leukocyte[14,22] or high monocyte[26] counts. Presence of circulating blasts at presentation had an unfavorable prognostic influence, as previously shown.[13,14,22] Finally, we were able to demonstrate that the adverse effect of advance age (age > 65 years) was not merely a demographic phenomenon but probably an indication of decreased tolerance to the disease and its complications by the elderly.

An abnormal karyotype was associated with shorter survival in the current study. However, we are mindful of the difficulty obtaining assessable metaphases in PMF because of a "dry tap" during bone marrow biopsy. The negative prognostic influence of cytogenetic abnormalities in PMF has previously been pointed out.[18,23-25] In the series by Tefferi et al,[25] such adverse influence was observed for cytogenetic abnormalities as a whole, but when chromosome changes were analyzed separately, the unfavorable influence was restricted to trisomy 8 and deletion of 12p, while deletions of 13q and 20q were not associated with shorter survival. In our study, the prognostic influence of specific karyotypic alterations could not be analyzed, because detailed information on the type of abnormality was not available from all contributing centers.

The prognostic impact of *JAK*2V617F or its allele burden in PMF is currently being debated.[29-31] In one retrospective study of 152 patients,[29] shorter survival was associated with the presence of *JAK*2V617F, whereas Barosi et al,[30] in a prospective study of 174 patients, found a correlation between the mutation and evolution toward large splenomegaly, need for splenectomy, and frequency of leukemic transformation, but not survival. Similarly, in 117 patients from the Mayo Clinic,[31] no prognostic value for the *JAK*2 mutation was noted. In the 345 patients from the present study in which *JAK*2V617F mutational status was available, the presence of the mutation was not associated with either prognostic score or survival. Information on *JAK*2V617F allele burden was available in a small proportion of study patients, and differences among study centers regarding assay methodology and cell types used to measure allele burden prevent valid prognostic analysis using the particular parameter in the current study.

PMF patients have an increased number of CD34$^+$ cells in peripheral blood.[27] In one study,[27] a correlation between circulating CD34$^+$ cell count and patient risk group was noted, with the higher the number of such cells the more unfavorable the risk group, but such prognostic correlation was not confirmed in the series of the Mayo Clinic[28] or in the current study.

Several prognostic score systems for PMF have been proposed.[12,13,18,19,22,26] The most widely used is the "Lille score" reported by Dupriez et al,[22] which features 3 prognostic categories based on hemoglobin level and leukocyte count, median survivals in low-, intermediate-, and high-risk groups being 93, 26, and 13 months, respectively. Subsequent studies, including the current one, showed that the Lille score does not clearly separate intermediate- and high-risk patient groups. More recently,[26] the Mayo Clinic group tried to improve the Lille score by adding thrombocytopenia ($< 100 \times 10^9$/L) and monocytosis ($> 1 \times 10^9$/L) as additional adverse risk factors. This resulted in better, but still suboptimal, separation of intermediate- and high-risk categories. Finally, the scoring system by Cervantes et al,[12] applicable also to younger patients,[13] is based on hemoglobin level and the presence or absence of constitutional symptoms and circulating blasts. However, the value of this system is limited by its ability to identify only 2 risk groups; identification of an intermediate-risk group is important, as shown in other hematologic diseases such as chronic myeloid leukemia[51] or the myelodysplastic syndromes.[52]

Based on 5 parameters readily available at time of diagnosis, the current prognostic model identifies 4 prognostic groups in PMF that are clearly different with regard to survival. Accordingly, low- and high-risk patient groups, including more than one-fifth of the study patients each, displayed respective median survivals of approximately 11 and 2 years, whereas median survivals of patients in the 2 intermediate-risk disease categories were 8 and 4 years. This new prognostic model had higher discriminating power than that seen with previous scoring systems and showed high replicability and predictive accuracy. Of note, the 2 intermediate-risk groups showed no overlapping in the survival curves and also a different influence on relative survival. Indeed, in patients in the intermediate risk-1 group, the shortening in relative survival was observed only after 3 years of diagnosis, while in the intermediate risk-2 group, such an effect was evident since time of presentation, supporting the consideration of 2 instead of 1 intermediate-risk groups. Also of note, cytogenetic findings had additional prognostic value in these intermediate-risk group patients only.

The new PMF prognostic system has considerable practical implications. For example, for low-risk patients, who have an expected median survival that exceeds 11 years, the risk treatment-related mortality and morbidity from allo-SCT or the possible toxicity of new investigational drug therapy might not be justified. On the other hand, it is reasonable to recommend investigational drug therapy for all other patients and allo-SCT for high- or intermediate risk-2 patients. Obviously, such recommendations as well as our proposed prognostic system are open to change based on additional new information.

Acknowledgments

Authorship

Contribution: F.C. and A.T. designed research, interpreted results, and wrote the paper; A.P. performed the statistical analysis; and B.D., F.P., J.T.R., E.M., A.M.V., R.A.M., J.-L.D., G.B., and E.R. performed research and revised the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Francisco Cervantes, Hematology Department, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain; e-mail: fcervan@clinic.ub.es; or Ayalew Tefferi, Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905; e-mail: tefferi.ayalew@mayo.edu.

References

1. Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Leuk Res. 2007;31:737-740.

2. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol. 1999;17:2954-2970.

3. Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood. 1978;51:189-194.

4. Buschle M, Janssen JW, Drexler H, Lyons J, Anger B, Bartram CR. Evidence of pluripotent stem cell origin of idiopathic myelofibrosis: clonal analysis of a case characterized by a N-ras gene mutation. Leukemia. 1988;2:658-660.

5. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.

6. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.

7. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.

8. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:1140-1151.

9. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472-3476.

10. Guglielmelli P, Pancrazzi A, Bergamaschi G, et al. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol. 2007;137:244-247.

11. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County study, 1975-1995. Am J Hematol. 1999;61:10-15.

12. Cervantes F, Barosi G, Demory JL, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol. 1998;102:684-690.

13. Cervantes F, Pereira A, Esteve J, et al. Identification of "long-lived" and "short-lived" patients at presentation of primary myelofibrosis. Br J Haematol. 1997;97:635-640.

14. Tefferi A, Huang J, Schwager S, et al. Validation and comparison of contemporary prognostic models in primary myelofibrosis. Analysis based on 334 patients from a single institution. Cancer. 2007;109:2083-2088.

15. Barosi G, Berzuini C, Liberato LN, Costa A, Polino G, Ascari E. A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol. 1988;70:397-401.

16. Visani G, Finelli C, Castelli U, et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol. 1990;75:4-9.

17. Rupoli S, Da Lio L, Sisti S, et al. Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival. Ann Hematol. 1994;68:205-212.

18. Reilly JT, Snowden JA, Spearing RL, et al. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol. 1997;98:96-102.

19. Kvasnicka HM, Thiele J, Werden C, Zankovich R, Diehl V, Fischer R. Prognostic factors in idiopathic (primary) osteomyelofibrosis. Cancer. 1997;80:708-719.

20. Njoku OS, Lewis SM, Catovsky D, Gordon-Smith EC. Anaemia in myelofibrosis: its value in prognosis. Br J Haematol. 1983;54:79-89.

21. Varki A, Lottenberg R, Griffith R, Reinhard E. The syndrome of idiopathic myelofibrosis: a clinico-pathologic review with emphasis on the prognostic variables predicting survival. Medicine (Baltimore). 1983;62:353-371.

22. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88:1013-1018.

23. Miller JB, Testa JR, Lindgren V, Rowley JD. The pattern and clinical significance of karyotypic abnormalities in patients with idiopathic and post-polycythemic myelofibrosis. Cancer. 1985;55:582-591.

24. Demory JL, Dupriez B, Fenaux P, et al. Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases. Blood. 1988;72:855-859.

25. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li Ch-Y, Dewald GW. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;113:763-771.

26. Elliott MA, Verstovsek S, Dingli D, et al. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res. 2007;31:1503-1509.

27. Barosi G, Viarengo G, Pecci A, et al. Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia. Blood. 2001;98:3249-3255.

28. Arora B, Sirhan S, Hover JD, Mesa RA, Tefferi A. Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients. Br J Haematol. 2005;128:42-48.

29. Campbell PJ, Griesshammer M, Döhner K, et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood. 2006;107:2098-2100.

30. Barosi G, Bergamaschi G, Marchetti M, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood. 2007;110:4030-4036.

31. Tefferi A, Lasho TL, Schwager SM, et al. The JAK2 V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol. 2005;131:320-328.

32. Cervantes F, Mesa R, Barosi G. New and old treatment modalities in primary myelofibrosis. Cancer J. 2007;13:377-383.

33. Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societé Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood. 1999;93:2831-2838.

34. Kerbauy DM, Gooley TA, Sale GE, et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant. 2007;13:355-365.

35. Rondelli D, Barosi G, Bacigalupo A, et al. Allogeneic stem cell transplantation with reduced intensity conditioning in intermediate and high-risk patients with myelofibrosis with myeloid metaplasia. Blood. 2005;105:4115-4119.

36. Kröger N, Zabelina T, Schieder H, et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol. 2005;128:690-697.

37. Merup M, Lazarevic V, Nahi H, et al. Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. Br J Haematol. 2006;135:367-373.

38. Kroeger N, Holler E, Kobbe G, et al. Dose-reduced conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis. Results from a multicenter prospective trial of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation [abstract 683]. Blood. 2007;110:210a.

39. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092-1097.

40. Thiele J, Kvasnicka HM, Boeltken B, Zankovich R, Diehl V, Fischer R. Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF)—a clinicopathological study. Leukemia. 1999;13:1741-1748.

41. Wilkins BS, Erber WN, Bareford D, et al. Bone marrow pathology in essential thrombocythe-

mia: interobserver reliability and utility for identifying disease subtypes. Blood. 2008;111: 60-70.

42. Spivak J, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis and primary myelofibrosis: an alternative proposal. Blood. 2008; 112:231-239.

43. Kaplan E, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.

44. Cox D. Regression models and life-tables [with discussion]. J R Stat Soc B. 1972;34:187-220.

45. Grambsch PM, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515-516.

46. Harrell FE Jr, Lee KL, Mark DR. Tutorial in biostatistics—multivariate prognostic models: issues in developing models, evaluating assumptions and adequacy and reducing errors. Stat Med. 1996; 15:361-387.

47. Cervantes F, Robertson JE, Rozman C, et al. Long-term survivors in chronic granulocytic leukemia: a study by the International CGL Study Group. Br J Haematol. 1994;87:293-300.

48. Hakulinen T. Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics. 1982; 38:933-942.

49. Hakulinen TR, Dyba TA. Recent developments in relative survival analysis. In: Taktak AFG, Fisher AC, eds. Outcome Prediction in Cancer. Amsterdam, The Netherlands: Elsevier; 2007:43-46.

50. Dickman P, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Stat Med. 2004;23:51-64.

51. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984;63:789-799.

52. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89: 2079-2088.